logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges

Chavan VV, Dalal A, Nagaraja SB, Thekkur P, Mansoor H,  et al.
2020-06-16 • PLOS One
2020-06-16 • PLOS One
Background
Imipenem, an intravenous antibiotic is recommended for use in drug resistant tuberculosis (DR-TB) when an effective regimen with combination of other second line drugs is...
Journal Article
|
Research

Yield of systematic longitudinal screening of household contacts of pre-extensively drug resistant (PreXDR) and extensively drug resistant (XDR) tuberculosis patients in Mumbai, India

Paryani R, Gupta V, Singh P, Verma M, Sheikh S,  et al.
2020-05-26 • Tropical Medicine and Infectious Disease
2020-05-26 • Tropical Medicine and Infectious Disease
While risk of tuberculosis (TB) is high among household contacts (HHCs) of pre-extensively drug resistant (pre-XDR) TB and XDR-TB, data on yield of systematic longitudinal screening are ...
Journal Article
|
Research

Poor Outcomes in a Cohort of HIV-Infected Adolescents Undergoing Treatment for Multidrug-Resistant Tuberculosis in Mumbai, India

Isaakidis P, Paryani R, Khan S, Mansoor H, Manglani M,  et al.
2013-07-01 • PLOS One
2013-07-01 • PLOS One
Poor Outcomes in a Cohort of HIV-Infected Adolescents
Undergoing Treatment for Multidrug-Resistant
Tuberculosis in Mumbai, India
Petros Isaakidis1*, Roma Paryani1, Samsuddin ...
Journal Article
|
Research

One step forward: successful end-of-treatment outcomes of patients with drug-resistant tuberculosis who received concomitant bedaquiline and delamanid in Mumbai, India

Das M, Dalal A, Laxmeshwar C, Ravi S, Mamnoon F,  et al.
2021-11-02 • Clinical Infectious Diseases
2021-11-02 • Clinical Infectious Diseases
BACKGROUND
The Médecins Sans Frontières clinic in Mumbai, India, has been providing concomitant bedaquiline (BDQ) and delamanid (DLM) in treatment regimen for patients with drug-resi...
Journal Article
|
Research

One step forward: Successful end-of-treatment outcomes of drug-resistant TB patients who received concomitant bedaquiline and delamanid in Mumbai, India

Das M, Dalal A, Laxmeshwar C, Ravi S, Mamnoon F,  et al.
2020-10-20 • Clinical Infectious Diseases
2020-10-20 • Clinical Infectious Diseases
Background
Médecins Sans Frontières clinic in Mumbai, India has been providing concomitant Bedaquiline (BDQ) and Delamanid (DLM) in treatment regimen for patients with drug-resistan...
Journal Article
|
Research

Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India

Isaakidis P, Varghese B, Mansoor H, Cox HS, Ladomirska J,  et al.
2011-07-11 • PLOS One
2011-07-11 • PLOS One
Significant adverse events (AE) have been reported in patients receiving medications for multidrug- and extensively-drug-resistant tuberculosis (MDR-TB & XDR-TB). However, there is littl...